These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 27329639)

  • 21. Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis.
    Wang W; Lin P
    Pathology; 2020 Jan; 52(1):6-14. PubMed ID: 31767130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
    Abeykoon JP; Paludo J; King RL; Ansell SM; Gertz MA; LaPlant BR; Halvorson AE; Gonsalves WI; Dingli D; Fang H; Rajkumar SV; Lacy MQ; He R; Kourelis T; Reeder CB; Novak AJ; McPhail ED; Viswanatha DS; Witzig TE; Go RS; Habermann TM; Buadi FK; Dispenzieri A; Leung N; Lin Y; Thompson CA; Hayman SR; Kyle RA; Kumar SK; Kapoor P
    Am J Hematol; 2018 Feb; 93(2):187-194. PubMed ID: 29080258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.
    Mori N; Ohwashi M; Yoshinaga K; Mitsuhashi K; Tanaka N; Teramura M; Okada M; Shiseki M; Tanaka J; Motoji T
    PLoS One; 2013; 8(11):e80088. PubMed ID: 24224040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis.
    Martino G; Marra A; Ascani S; Sportoletti P
    Ann Hematol; 2019 Jun; 98(6):1507-1508. PubMed ID: 30426157
    [No Abstract]   [Full Text] [Related]  

  • 25. [Nodal lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia: a clinicopathological and prognostical study].
    Zhang DD; Hu PZ; Li P; Jiang GZ; Yin YH; Wang GN; Zhao WG; Zhang YP; Li WC
    Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):592-597. PubMed ID: 34078045
    [No Abstract]   [Full Text] [Related]  

  • 26. Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.
    Shin DW; Kim SM; Kim JA; Park HS; Hwang SM; Im K; Kim S; Kim J; Kwon S; Yoon SS; Lee DS
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e496-e505. PubMed ID: 31221512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
    Varettoni M; Arcaini L; Zibellini S; Boveri E; Rattotti S; Riboni R; Corso A; Orlandi E; Bonfichi M; Gotti M; Pascutto C; Mangiacavalli S; Croci G; Fiaccadori V; Morello L; Guerrera ML; Paulli M; Cazzola M
    Blood; 2013 Mar; 121(13):2522-8. PubMed ID: 23355535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.
    Growkova K; Kufová Z; Sevcikova T; Filipová J; Kascak M; Jelínek T; Grosicki S; Barchnicka A; Roziaková Ľ; Mistrík M; Simicek M; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):81-91. PubMed ID: 28903575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
    Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
    Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphoplasmacytic lymphoma and marginal zone lymphoma in the bone marrow: paratrabecular involvement as an important distinguishing feature.
    Bassarova A; Trøen G; Spetalen S; Micci F; Tierens A; Delabie J
    Am J Clin Pathol; 2015 Jun; 143(6):797-806. PubMed ID: 25972321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
    Minzenmayer AN; Miranda RN; Powell PR; Parekh PK
    J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
    Xu L; Hunter ZR; Yang G; Cao Y; Liu X; Manning R; Tripsas C; Chen J; Patterson CJ; Kluk M; Kanan S; Castillo J; Lindeman N; Treon SP
    Leukemia; 2014 Aug; 28(8):1698-704. PubMed ID: 24509637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of the MYD88
    Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX
    Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.
    Insuasti-Beltran G; Gale JM; Wilson CS; Foucar K; Czuchlewski DR
    Arch Pathol Lab Med; 2015 Aug; 139(8):1035-41. PubMed ID: 26230596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
    Kapoor P; Paludo J; Ansell SM
    Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia.
    Jiménez C; Sebastián E; Chillón MC; Giraldo P; Mariano Hernández J; Escalante F; González-López TJ; Aguilera C; de Coca AG; Murillo I; Alcoceba M; Balanzategui A; Sarasquete ME; Corral R; Marín LA; Paiva B; Ocio EM; Gutiérrez NC; González M; San Miguel JF; García-Sanz R
    Leukemia; 2013 Aug; 27(8):1722-8. PubMed ID: 23446312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Composite monoclonal B-cell lymphocytosis and MYD88 L265P-positive lymphoplasmacytic lymphoma in a patient with IgM light chain amyloidosis: Case report.
    Oishi N; Inoue T; Odate T; Mochizuki K; Ohashi K; Kirito K; Kondo T
    Pathol Int; 2020 Jul; 70(7):458-462. PubMed ID: 32323419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis.
    Rossi D
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):113-8. PubMed ID: 25696843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MYD88 L265P mutation analysis is a useful diagnostic adjunct for lymphoplasmacytic lymphoma with pleural effusion.
    Pan ST; Wang RC; Kuo CC; Hsieh YC; Su YZ; Chuang SS
    Pathol Int; 2019 Oct; 69(10):601-607. PubMed ID: 31556196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.